Clinical Trial Update: Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab in combination with metformin as first-line therapy for advanced non-small cell lung cancer refractory to chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)
• metformin (metformin)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN